Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/metastatic non–small‐cell lung cancer (NSCLC) without EGFR/A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2021-05, Vol.148 (9), p.2313-2320
Hauptverfasser:	Wu, Yi‐Long, Zhang, Li, Fan, Yun, Zhou, JianYing, Zhou, Qing, Li, Wei, Hu, ChengPing, Chen, GongYan, Zhang, Xin, Zhou, CaiCun, Dang, Thao, Sadowski, Sara, Kush, Debra A., Zhou, Yu, Li, Ben, Mok, Tony
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Apoptosis Cancer Cancer Therapy and Prevention Carboplatin Chemotherapy Clinical trials Epidermal growth factor receptors Histology Immunotherapy Lung cancer Medical research Metastases Metastasis Monoclonal antibodies Non-small cell lung carcinoma non–small‐cell lung cancer Paclitaxel Patients PD-L1 protein Pembrolizumab programmed death ligand 1 Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!